



# Citi Pharma Limited

February 28, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi.

## Financial results for the half year ended December 31, 2024

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on February 28, 2025 at Lahore have approved the financial statements for the half year ended on December 31, 2024 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

### Financial Performance:

While reviewing the Company financial performance for the half year ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

Financial results of the company for the half year ended December 31, 2024 are enclosed.

Half Yearly report of the Company for the period ended December 31, 2024 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

  
Ghulam Dastgeer  
Company Secretary



Cc:

Executive Director/HOD, Offsite-II, Department  
Supervision Division, Securities & Exchange Commission of Pakistan



# Citi Pharma Limited

CITI PHARMA LIMITED  
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)  
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

Notes	Three month ended		Six Month Ended	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
	-----Rupees-----			
Sales- Net	3,534,432,320	3,275,164,830	6,750,077,137	5,976,393,097
Cost of Sales	(2,995,298,629)	(2,649,999,438)	(5,791,430,427)	(5,104,759,709)
Gross Profit	539,133,691	625,165,392	967,646,710	871,633,388
Administrative Expenses	58,249,282	51,252,284	104,646,233	99,514,835
Selling Expenses	43,131,925	31,504,344	83,827,444	70,138,398
	(101,381,207)	(82,756,628)	(188,473,657)	(169,653,233)
Operating Profit	437,752,484	542,408,764	779,173,053	701,980,155
Financial (Cost) / Income	(67,868,193)	(70,185,726)	(132,441,809)	(156,974,215)
	369,884,293	472,243,038	646,731,244	545,005,940
Other Income/(Loss)	50,423,119	157,403,690	147,644,938	263,611,872
	420,307,412	629,646,728	794,376,182	808,617,812
Other Expenses	(26,133,137)	(43,148,644)	(54,904,003)	(55,493,379)
Profit before income taxes and final taxes	394,174,275	586,498,084	734,472,179	753,124,433
Taxation - Final taxes	-	(255,267)	(4,004)	(255,267)
Profit before income tax	394,174,275	586,242,817	734,468,175	752,869,166
Taxation - Income tax	(137,195,683)	(210,642,174)	(275,996,570)	(282,816,983)
Profit after income tax	256,978,592	375,600,644	458,471,605	470,052,183
Earnings per share (EPS) - Basic and Diluted	1.12	1.64	2.01	2.06



588 - Q, Johar Town, Lahore - Pakistan



31KM, Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk